Hoth Therapeutics

HOTHPhase 2

Hoth Therapeutics is a publicly traded biopharma company with a patient-centric mission to develop innovative treatments that improve quality of life. Its core asset is the BioLexa Platform, a topical treatment for atopic dermatitis, and it is expanding its pipeline into oncology, neurology, and inflammatory dermatology. The company operates as a pre-revenue, clinical-stage entity focused on addressing significant unmet medical needs through targeted therapeutic approaches.

Market Cap

$14.2M

Focus

Small Molecules

HOTH · Stock Price

USD 0.9115.84 (-94.54%)

Historical price data

AI Company Overview

Technology Platform

The BioLexa Platform is a proprietary, topical treatment technology focused on developing targeted therapeutics for dermatological conditions like atopic dermatitis and chronic wound disorders.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
HT-001 2% Topical Gel + HT-001 1% Topical Gel + HT-001 0.5% Topical Gel + HT-001...	Acneiform Eruption Due to Chemical	Phase 2
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + Gentamicin	Atopic Dermatitis	Phase 1

Funding History

Total raised: $16M

PIPE$8MUndisclosedMar 15, 2021

IPO$6MUndisclosedFeb 15, 2019

Seed$2MUndisclosedJun 15, 2018

Opportunities

The primary opportunity is successfully developing and commercializing the BioLexa Platform for the large atopic dermatitis market.

Pipeline expansion into oncology and neurology offers long-term value creation and diversification.

Strategic partnerships or an acquisition are potential exit opportunities.

Risk Factors

High risk of clinical trial failure for its lead and only detailed asset.

Heavy reliance on public equity markets for funding creates dilution and financing risk.

Faces intense competition from large pharma in its target therapeutic areas.

Competitive Landscape

Competes in atopic dermatitis against large pharma (Sanofi, Pfizer, AbbVie) with approved systemic therapies and numerous biotechs. Differentiation hinges on the novel, topical BioLexa Platform offering a potential efficacy/safety advantage. As a micro-cap, it lacks the resources of its competitors.